OncoAlert’s Post

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer out on Nature Medicine Trial analyzed circulating tumor DNA🧬 and germline DNA in patients randomized to receive androgen receptor pathway inhibitors (ARPIs)💊, taxanes, or physician's choice of treatment🇸🇪 ✅The primary endpoint, time to no longer clinically benefitting (NLCB), was met after 218 randomizations. ARPIs showed significantly longer time to NLCB (11.1 months) and overall survival (38.7 months) compared to taxanes and physician's choice treatments. ✅Biomarker analysis revealed that ARPIs were especially effective in AR-negative, TP53 wild-type, and TMPRSS2–ERG fusion-positive patients. https://lnkd.in/gTupBiXB Bram De Laere Venkatesh Chellappa Mahsan Banijamali Céline Schelstraete Jan Pieter Vanwelkenhuyzen Hjälm-Eriksson Marie Linn Pettersson Anders Ullén Nicolaas Lumen Gunilla Enblad Camilla Thellenberg-Karlsson Peter Schatteman 'christophe ghysel' Brieuc Sautois Wendy De Roock, MD, PhD (she/her) Siska Van Bruwaene Jochen Darras Michiel Strijbos Ashkan Mortezavi Jan Oldenburg Piet Ost Henrik Gronberg Johan Lindberg